Skip to main content

Table 1 Patient characteristics at baseline (N = 89)

From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Characteristic N %
Sex   
 Male 49 55.1
 Female 40 44.9
Age   
 Median 62  
 Range 36-80  
ECOG PS   
 0 66 74.2
 1 23 25.8
Primary tumor   
 Colon 56 62.9
 Rectum 33 37.1
Histological classification   
 Tubular adenocarcinoma (well-differentiated type) 27 30.3
 Tubular adenocarcinoma (moderately-differentiated type) 50 56.2
 Poorly-differentiated adenocarcinoma 9 10.1
 Mucinous adenocarcinoma 3 3.4
Number of metastatic sites   
 1 37 41.6
 2≤ 52 58.4
UGT1A1*28/*6 polymorphism   
 Wild-type group 52 58.4
 Heterozygous group 37 41.6
First-line treatment   
 Refractory (PD) / intolerable (adverse event) to oxaliplatin-based treatment 46/43 51.7/48.3
 With/without bevacizumab 69/20 77.5/22.5